English
 
Help Privacy Policy Disclaimer
  Advanced SearchBrowse

Item

ITEM ACTIONSEXPORT
 
 
DownloadE-Mail
 Local TagsRelease HistoryDetailsSummary
  Monitoring reversible and irreversible EGFR inhibition with erlotinib and afatinib in a patient with EGFR-mutated non-small cell lung cancer (NSCLC) using sequential [ 18F]fluorothymidine (FLT-)PET

Scheffler, M., Kobe, C., Zander, T., Nogova, L., Kahraman, D., Thomas, R. K., et al. (2012). Monitoring reversible and irreversible EGFR inhibition with erlotinib and afatinib in a patient with EGFR-mutated non-small cell lung cancer (NSCLC) using sequential [ 18F]fluorothymidine (FLT-)PET. Lung Cancer, 77(3), 617-620. doi:10.1016/j.lungcan.2012.05.110.

Item is

 

show all hide all

Basic

show hide
Item Permalink: https://hdl.handle.net/11858/00-001M-0000-0026-D6EF-E Version Permalink: https://hdl.handle.net/11858/00-001M-0000-0026-D6F0-8
Genre: Journal Article

Files

show Files

Locators

show

Creators

show
hide
 Creators:
Scheffler, Matthias1, Author
Kobe, Carsten1, Author
Zander, Thomas2, Author           
Nogova, Lucia1, Author
Kahraman, Deniz1, Author
Thomas, Roman K.3, Author           
Neumaier, Bernd4, Author           
Dietlein, Markus5, Author           
Wolf, Jürgen1, Author
Affiliations:
1a Department I for Internal Medicine, University Hospital of Cologne, Germany b Center for Integrated Oncology Köln Bonn, Germany c Clinic for Nuclear Medicine, University Hospital of Cologne, Germany, ou_persistent22              
2Klinisches PET, Neurologische Abteilung, Max-Planck-Institut für neurologische Forschung, Managing Director: D. Yves von Cramon, Max Planck Institute for Metabolism Research, Managing Director: Jens Brüning, Max Planck Society, ou_2149663              
3Funktionelle Krebsgenomforschung, Junior Research Groups, Max-Planck-Institut für neurologische Forschung, Managing Director: D. Yves von Cramon, Max Planck Institute for Metabolism Research, Managing Director: Jens Brüning, Max Planck Society, ou_2149656              
4Radiochemistry, Scientific Services and Development, Max Planck Institute for Metabolism Research, Managing Director: Jens Brüning, Max Planck Society, ou_2149672              
5Translational Neurocircuitry, Research Groups, Max Planck Institute for Metabolism Research, Managing Director: Jens Brüning, Max Planck Society, ou_2149668              

Content

show
hide
Free keywords: -
 Abstract: © 2012 Elsevier Ireland Ltd. All rights reserved.

Details

show
hide
Language(s): eng - English
 Dates: 2012
 Publication Status: Issued
 Pages: -
 Publishing info: -
 Table of Contents: -
 Rev. Type: -
 Identifiers: eDoc: 610606
DOI: 10.1016/j.lungcan.2012.05.110
 Degree: -

Event

show

Legal Case

show

Project information

show

Source 1

show
hide
Title: Lung Cancer
Source Genre: Journal
 Creator(s):
Affiliations:
Publ. Info: -
Pages: - Volume / Issue: 77 (3) Sequence Number: - Start / End Page: 617 - 620 Identifier: ISSN: 01695002